The second thing is based on a comment in the pape

Quote:

---

The second thing is based on a comment in the paper that ""CCR5 haplotype analysis is suggestive that specific haplotypes may be better suited for the 700mg dose of leronlimab." They identified a small number of these patients in the study, and boy did they respond well to the larger dose. The authors used red for increases, and green for decreases, and so the 700mg haplotype column literally lights up like a Christmas tree! While I confess I don't know what a haplotype is, apparently Cytodyn can test for and identify as prospective patients. So they are finding more and more information about dosage and who responds, which they can actionably use in trial design as well as in the clinic (eventually).

---

There are certain CCR5 haplotypes (genetic mutations) that cause an expression of CCR5 far above normal. The entire 700mg group would still be dragged down by deleted alleles. However any haplotype groups that overexpressed CCR5 would show benefit because of course they're obviously not CCR5 delta 32 deletions.